Greenwich Lifesciences Inc reports results for the quarter ended in December - Earnings Summary

Greenwich Lifesciences

17/04/2024 11:19

* Greenwich Lifesciences Inc  GLSI.OQ  reported a quarterly
adjusted loss of 21 cents​​ per share for the quarter ended in
December, higher than the same quarter last year, when the
company reported EPS of -22 cents.  The lone analyst forecast
for the quarter was for a loss of 20 cents per share. 
    * Reported revenue was zero​; analysts expected zero. 
    * Greenwich Lifesciences Inc's reported EPS for the quarter
was a
loss of 21 cents​.
    * The company reported a quarterly loss of $2.75 million.
    * Greenwich Lifesciences Inc shares had fallen by 27.7% this
quarter and gained 37.1% so far this year.

FORECAST CHANGES
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Greenwich
Lifesciences Inc is $36.00 
This summary was machine generated from LSEG data April 17 at
10:19 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.20          -0.21          Missed
 Jun. 30 2023      -0.23          -0.13          Beat
 Mar. 31 2023      -0.23          -0.16          Beat